search button

Amplification of the bromodomain-containing protein 4 gene in ovarian high‑grade serous carcinoma is associated with worse prognosis and survival

  • Authors:
    • Duygu Ucar
    • Douglas I. Lin

  • View Affiliations

  • Published online on: August 14, 2015     https://doi.org/10.3892/mco.2015.622
  • Pages: 1291-1294
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

High‑grade serous carcinoma (HGSC) of the ovary is an aggressive and devastating neoplasm and the identification of novel therapeutic targets may result in a significant decrease in patient morbidity and mortality. Over the last few years, chromatin regulators have become attractive targets for cancer therapy. More specifically, bromodomain-containing protein 4 (BRD4), a protein that is associated with acetylated chromatin and transcriptional activation, has been shown to selectively regulate the transcription of key oncogenic drivers, such as CMYC, in several tumor types. The Cancer Genome Atlas (TCGA) project has molecularly characterized the genome of ovarian serous carcinomas, which enabled us to study the association of genomic alterations of BRD4 with patient survival and clinicopathological characteristics. Our analysis using clinical and genomic data from the TCGA ovarian carcinoma samples revealed that somatic amplification of BRD4 (observed in 12% of the cases) was correlated with increased BRD4 mRNA levels and is significantly associated with worse overall and progression‑free survival compared to wild‑type cases. These findings support the hypothesis that future studies and trials investigating newly developed BRD4 inhibitors are required in a subset of patients with ovarian HGSC.
View Figures
View References

Related Articles

Journal Cover

November-2015
Volume 3 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.4
  • Ranked
    (total number of cites)
  • CiteScore: 2.8
  • CiteScore Rank: Q3: #250/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.55
  • SCImago Journal Rank (SJR): 0.446
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Ucar D and Lin DI: Amplification of the bromodomain-containing protein 4 gene in ovarian high‑grade serous carcinoma is associated with worse prognosis and survival. Mol Clin Oncol 3: 1291-1294, 2015.
APA
Ucar, D., & Lin, D.I. (2015). Amplification of the bromodomain-containing protein 4 gene in ovarian high‑grade serous carcinoma is associated with worse prognosis and survival. Molecular and Clinical Oncology, 3, 1291-1294. https://doi.org/10.3892/mco.2015.622
MLA
Ucar, D., Lin, D. I."Amplification of the bromodomain-containing protein 4 gene in ovarian high‑grade serous carcinoma is associated with worse prognosis and survival". Molecular and Clinical Oncology 3.6 (2015): 1291-1294.
Chicago
Ucar, D., Lin, D. I."Amplification of the bromodomain-containing protein 4 gene in ovarian high‑grade serous carcinoma is associated with worse prognosis and survival". Molecular and Clinical Oncology 3, no. 6 (2015): 1291-1294. https://doi.org/10.3892/mco.2015.622